autoimmune hemolytic anemia
autoimmune hemolytic anemia
Explore linked clinical trials. Standard reference: MONDO:002010841 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| A Study to Investigate the Efficacy, Safety, and Pharmacokinetics of Oral Rilzabrutinib Compared With Placebo in Participants 18 Years of Age and Older With Warm Autoimmune Hemolytic Anemia | Hemic and Lymphatic Diseases, anemia, autoimmune disease, autoimmune hemolytic anemia, hematologic disorder, hemolytic anemia, immune system disorder | Recruiting | Phase 3 | 2026-09-22 | NCT07086976 | |
| META 10-19 in Patients With Relapsed/Refractory Autoimmune Hemolytic Anemia | Hemic and Lymphatic Diseases, anemia, autoimmune disease, autoimmune hemolytic anemia, hematologic disorder, hemolytic anemia, immune system disorder | Not yet recruiting | Early phase 1 | 2026-09-21 | NCT07689604 | |
| Brain Cognitive Network Abnormalities in Anemia Patients Using fNIRS | Bone Marrow Failure Disorders, Hemic and Lymphatic Diseases, anemia, aplastic anemia, autoimmune disease, autoimmune hemolytic anemia, bone marrow disorder, hematologic disorder, hemolytic anemia, immune system disorder, myelodysplastic syndrome | Recruiting | Not stated | 2026-09-18 | NCT07578675 | |
| Phase 1 Study of F182112 in Relapsed/Refractory Autoimmune Hemolytic Anemia | Hemic and Lymphatic Diseases, anemia, autoimmune disease, autoimmune hemolytic anemia, hematologic disorder, hemolytic anemia, immune system disorder | Not yet recruiting | Phase 1 | 2026-09-11 | NCT07816341 | |
| OM336 in Autoimmune Cytopenias | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, anemia, autoimmune disease, autoimmune hemolytic anemia, blood coagulation disease, blood platelet disease, hematologic disorder, hemolytic anemia, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Recruiting | Phase 1 | 2026-09-03 | NCT07083960 | |
| HY001N for Patients With Autoimmune Hemolytic Anemia After Failure ≥3 Lines of Therapy. | Hemic and Lymphatic Diseases, anemia, autoimmune disease, autoimmune hemolytic anemia, hematologic disorder, hemolytic anemia, immune system disorder | Recruiting | Phase 1 | 2026-08-05 | NCT07748533 | |
| A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia | B-cell chronic lymphocytic leukemia, B-cell neoplasm, Burkitt lymphoma, Chronic Disease, DNA Virus Infections, Disease Attributes, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Tumor Virus Infections, anemia, autoimmune disease, autoimmune hemolytic anemia, hematologic disorder, hemolytic anemia, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, neoplasm, viral infectious disease | Recruiting | Early phase 1 | 2026-07-20 | NCT07205315 | |
| Study of Zola-cel (BMS-986353), in Participants With Autoimmune Cytopenia (Breakfree-AiCE) | Hemic and Lymphatic Diseases, anemia, autoimmune disease, autoimmune hemolytic anemia, hematologic disorder, hemolytic anemia, immune system disorder | Not yet recruiting | Phase 2 | 2026-07-09 | NCT07603557 | |
| Orelabrutinib in the Treatment of Relapsed/Refractory AIHA | Hemic and Lymphatic Diseases, anemia, autoimmune disease, autoimmune hemolytic anemia, hematologic disorder, hemolytic anemia, immune system disorder | Recruiting | Phase 2 | 2026-06-16 | NCT07453368 | |
| Evaluation of Safety, Pharmacokinetics and Pharmacodynamics of Arnovie101, an mRNA-LNP-Based In Vivo CAR-T Therapy, for the Treatment of B Cell-Mediated Autoimmune Diseases (SLE and AIHA) | Hemic and Lymphatic Diseases, Skin and Connective Tissue Diseases, anemia, autoimmune disease, autoimmune hemolytic anemia, connective tissue disorder, hematologic disorder, hemolytic anemia, immune system disorder, systemic lupus erythematosus | Recruiting | Early phase 1 | 2026-06-05 | NCT07629596 | |
| CD20 Monoclonal Antibody Combined With BTK Inhibitor for the Treatment of Refractory Immune-related Cytopenia | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, anemia, autoimmune disease, autoimmune hemolytic anemia, blood coagulation disease, blood platelet disease, hematologic disorder, hemolytic anemia, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Not yet recruiting | Phase 1 | 2026-05-22 | NCT07574073 | |
| IASO206 in Patients With Relapsed/Refractory Autoimmune Hemolytic Anemia | Disease Attributes, Hemic and Lymphatic Diseases, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Recurrence, anemia, autoimmune disease, autoimmune hemolytic anemia, hematologic disorder, hemolytic anemia, immune system disorder | Not yet recruiting | Phase 1 | 2026-05-13 | NCT07585071 | |
| Acalabrutinib for the Treatment of Relapsed or Refractory Autoimmune Hemolytic Anemia in Patients With Chronic Lymphocytic Leukemia | B-cell chronic lymphocytic leukemia, Chronic Disease, Disease Attributes, Hemic and Lymphatic Diseases, Leukemia, B-Cell, Neoplasms by Histologic Type, Pathologic Processes, Pathological Conditions, Signs and Symptoms, anemia, autoimmune disease, autoimmune hemolytic anemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, hematologic disorder, hemolytic anemia, immune system disorder, immunoproliferative disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoproliferative syndrome, neoplasm | Active, not recruiting | Phase 2 | 2026-05-06 | NCT04657094 | |
| Cold Agglutinin Disease Real World Evidence Registry | Hemic and Lymphatic Diseases, anemia, autoimmune disease, autoimmune hemolytic anemia, hematologic disorder, hemolytic anemia, immune system disorder | Active, not recruiting | Not stated | 2026-04-22 | NCT05791708 | |
| A Multicenter, Prospective, Randomized Controlled Study Comparing Glucocorticoid Combined With Sirolimus With Monotherapy of Glucocorticoid in the Treatment of Newly Diagnosed Mild Autoimmune Hemolytic Anemia | Hemic and Lymphatic Diseases, anemia, autoimmune disease, autoimmune hemolytic anemia, hematologic disorder, hemolytic anemia, immune system disorder | Not yet recruiting | Not applicable | 2026-04-08 | NCT07518277 | |
| Research on YTS109 Cell in Patients With Recurrent/Refractory Autoimmune Hemolytic Anemia | Hemic and Lymphatic Diseases, anemia, autoimmune disease, autoimmune hemolytic anemia, hematologic disorder, hemolytic anemia, immune system disorder | Not yet recruiting | Phase 1 | 2026-03-06 | NCT07453836 | |
| UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological Diseases | Evans syndrome, Hemic and Lymphatic Diseases, anemia, autoimmune disease, autoimmune hemolytic anemia, hematologic disorder, hemolytic anemia, immune system disorder | Recruiting | Early phase 1 | 2026-03-02 | NCT07441525 | |
| National Longitudinal Cohort of Hematological Diseases | Blood Protein Disorders, Bone Marrow Failure Disorders, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Hemic and Lymphatic Diseases, Hemoglobinuria, Paroxysmal, Leukemia, Large Granular Lymphocytic, Myeloproliferative Disorders, Neoplasms by Histologic Type, T-cell leukemia, X-linked disease, acute myeloid leukemia, anemia, aplastic anemia, autoimmune disease, autoimmune hemolytic anemia, blood coagulation disease, blood platelet disease, bone marrow disorder, cardiovascular disorder, coagulation protein disease, essential thrombocythemia, hematologic disorder, hemolytic anemia, hemophilia A, hemophilia B, hemorrhagic disease, hereditary disease, immune system disorder, immunoproliferative disorder, inherited blood coagulation disorder, leukemia, lymphatic system disorder, lymphoid leukemia, lymphoma, lymphoproliferative syndrome, monoclonal gammopathy, myelodysplastic syndrome, myeloid leukemia, neoplasm, plasma cell neoplasm, thrombocytosis disease, vascular disorder, vascular hemostatic disease | Recruiting | Not stated | 2026-02-12 | NCT04645199 | |
| Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases | CNS demyelinating autoimmune disease, Hemic and Lymphatic Diseases, Sjogren syndrome, Skin and Connective Tissue Diseases, Stomatognathic Diseases, Xerostomia, anemia, arthritic joint disease, arthropathy, autoimmune disease, autoimmune disorder of the nervous system, autoimmune hemolytic anemia, connective tissue disorder, demyelinating disease, dry eye syndrome, eye disorder, hematologic disorder, hemolytic anemia, immune system disorder, lacrimal apparatus disorder, mouth disorder, multiple sclerosis, muscle tissue disorder, musculoskeletal system disorder, myositis disease, nervous system disorder, neuromuscular disease, rheumatic disorder, rheumatoid arthritis, salivary gland disorder, skin disorder, systemic lupus erythematosus, systemic sclerosis | Recruiting | Phase 1 | 2026-01-22 | NCT07361094 | |
| French Registry of Adult Patients With Immune Thrombocytopenia and Autoimmune Hemolytic Anemia | Cytopenia, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, anemia, autoimmune disease, autoimmune hemolytic anemia, blood coagulation disease, blood platelet disease, hematologic disorder, hemolytic anemia, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Recruiting | Not stated | 2025-12-31 | NCT02877706 | |
| Efficacy of Prolonged Anticoagulation for Primary Prevention of Venous Thromboembolic Disease in Autoimmune Hemolytic Anemia: a Prospective, Phase II, Randomized, Multicenter Study | Hemic and Lymphatic Diseases, anemia, autoimmune disease, autoimmune hemolytic anemia, hematologic disorder, hemolytic anemia, immune system disorder | Recruiting | Phase 2 | 2025-12-22 | NCT05089227 | |
| A Study of YTS109 Cell in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia | Hemic and Lymphatic Diseases, anemia, autoimmune disease, autoimmune hemolytic anemia, hematologic disorder, hemolytic anemia, immune system disorder | Not yet recruiting | Phase 1 | 2025-12-17 | NCT07287930 | |
| A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia | Cytopenia, Evans syndrome, Hemic and Lymphatic Diseases, Hemorrhage, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Purpura, Thrombocytopenic, Idiopathic, Signs and Symptoms, Skin Manifestations, anemia, autoimmune disease, autoimmune hemolytic anemia, blood coagulation disease, blood platelet disease, hematologic disorder, hemolytic anemia, hemorrhagic disease, immune system disorder, purpura, thrombocytopenia, thrombocytopenic purpura, thrombotic microangiopathy | Recruiting | Phase 1 / Phase 2 | 2025-12-17 | NCT07175493 | |
| A Single-arm Phase 2 Prospective Clinical Study of Enatumab in the Treatment of Relapsed/Refractory Warm Antibody Autoimmune Hemolytic Anemia | Hemic and Lymphatic Diseases, anemia, autoimmune disease, autoimmune hemolytic anemia, hematologic disorder, hemolytic anemia, immune system disorder | Not yet recruiting | Phase 2 | 2025-09-24 | NCT07190261 | |
| Inaticabtagene Autoleucel Injection in the Treatment of Autoimmune Hemolytic Anemia After Three or More Lines of Therapy | Hemic and Lymphatic Diseases, anemia, autoimmune disease, autoimmune hemolytic anemia, hematologic disorder, hemolytic anemia, immune system disorder | Not yet recruiting | Phase 1 | 2025-09-22 | NCT07091370 |